SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01657786

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting

Postoperative nausea and vomiting (PONV) is a common and distressing complication in patients undergoing general anesthesia. However, although 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists have significantly reduced PONV, it is reported that over 35% of patients treated with ondansetron experience PONV. Though the cause of failure in ondansetron treatment is not clear, the investigators assumed that polymorphism in the 5-HT3 receptor gene would contribute to such inter-individual variation. In this study, the investigators examine whether the polymorphisms of 5-HT3 receptor gene affect the efficacy of ondansetron to prevent PONV in patients undergoing general anesthesia for laparoscopic surgery.

NCT01657786 Post Operative Nausea and Vomiting
MeSH: Nausea Vomiting Postoperative Nausea and Vomiting
HPO: Nausea Vomiting

1 Interventions

Name: administration of ondanstron and screening of genomic DNA

Description: Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).

Type: Dietary Supplement

Ondansetron administration group


Primary Outcomes

Description: The incidence of PONV after ondansetron administration is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).

Measure: The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG)

Time: at first 2 h and 2-24 h after surgery.

Single Group Assignment


There are 2 SNPs

SNPs


1 S253N

The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG). --- S253N ---

The incidence of PONV after ondansetron administration is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).. Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Post Operative Nausea and Vomiting Nausea Vomiting Postoperative Nausea and Vomiting null --- S253N ---


2 Y129S

The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG). --- S253N --- --- Y129S ---

The incidence of PONV after ondansetron administration is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).. Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Post Operative Nausea and Vomiting Nausea Vomiting Postoperative Nausea and Vomiting null --- S253N --- --- Y129S ---



HPO Nodes


HPO:
Nausea
Genes 39
CFH APC VHL SERPING1 CACNA1D HMBS SAA1 CD46 KCNA1 RET GLA FH MDH2 SLC7A7 TYMP CFI ALDOB SDHAF2 TMEM127 INHBA SLC1A3 CYP11B1 CYP11B2 KCNJ5 NAGS RRM2B POLG MAX SDHA SDHB SDHC KIF1B SDHD MGME1 HELLPAR ETFA FSHR ETFB ETFDH
Vomiting
Genes 181
PIGY CFH CACNA1A MPV17 FLNA RANBP2 HNF1A PDSS2 GALC GALE RARS GALT ACADL ACADM ATRX TCN2 ACADVL ACAT1 AVP AIMP1 INHBA AVPR2 PPM1D CYP11A1 CYP11B1 CYP11B2 RRM2B POLG ACP2 CYP24A1 ETFA ETFB ETFDH MC2R APC CD55 HLCS ELP1 ACTG2 FARSB CDH23 HMBS ALG11 GCDH BCKDHA BCKDHB RELA HMGCL CD46 DBH HMGCS2 MCCC2 AIP MCCC1 CPOX TXNRD2 SSR4 CPS1 DBT ACY1 SLC7A7 CPT2 TYMP CFI COQ2 HNF4A AQP2 BOLA3 SLC1A3 ZEB2 COA8 SHANK3 NDUFS1 F12 STAR PHGDH NDUFV1 NAGS NDUFS4 KRIT1 MLYCD PPOX HELLPAR MEN1 ARG1 IVD MMAA GHSR SLC6A8 TRMU MRPS7 MET NBAS STK11 SAA1 OTC CCM2 LIPA GK FBP1 OXCT1 ATP6 GLA SLC12A1 TRNC SLC12A3 COX1 BRAF COX2 COX3 EGFR ST3GAL5 SUGCT CYTB MTHFD1 BTD KCNJ1 ABCC8 ASL HPRT1 DGUOK DHCR7 SLC25A15 MRAP KCNJ11 ND1 UCP2 SAR1B ND2 SLC22A5 ATP6V0A4 ND3 ND4 NAXD ND5 ASS1 ND6 SCNN1A SCNN1B SCNN1G SERPING1 ALDH18A1 ACSF3 DLD ALG8 TRNF C11ORF95 PNPLA8 SMPD1 ALAD NR3C2 CLMP ALG3 HSD3B2 TRNK TRNL1 CTNS HADH CTNNB1 TRNQ TNFRSF1A TRNS1 TRNS2 TRNV TRNW PDCD10 ALDOB MMAB PCCA PCCB NNT D2HGDH NEUROG3 MMUT DGAT1 MVK ALPL OPLAH PMM2 FOXP3 MPI